Clinical Guidelines and Quality Measures

Healthcare Effectiveness Data and Information Set (HEDIS®)

Stool DNA (i.e. Cologuard) is one of the methods permitted as part of the National Committee for Quality Assurance’s (NCQA) Healthcare Effectiveness Data and Information Set* (HEDIS®) quality measure for colon cancer screening. HEDIS is a helpful tool used by more than 90% of health plans in America. The quality measures analyze the performance of healthcare services and care. The data and results are used to make improvements in the healthcare provider's quality of care and service. Third party guidelines and quality measures do not specifically “endorse” commercial products, and inclusion in same does not imply otherwise.

US Preventive Services Task Force (USPSTF)

Cologuard is included in the US Preventive Services Task Force (USPSTF) guidelines on colon cancer screening as of its June 2016 update.

The USPSTF strongly recommends colon cancer screening for people aged 50-75 (‘A’ rating), meaning the committee finds a substantial net benefit in colon cancer screening.

Cologuard is included in the guidelines as a screening option with a three-year interval on equal standing among the other colon cancer screening options, including colonoscopy, CT colonography, flexible sigmoidoscopy, flexible sigmoidoscopy with FIT, gFOBT, and FIT.

Read the full USPSTF guidance as published in JAMA »

American Cancer Society (ACS)

Cologuard is included in American Cancer Society's Colorectal Cancer Prevention and Early Detection Guidelines. The guidelines include Cologuard in a recommended list of screening options.

ACS guidelines also reflect the Centers for Medicare and Medicaid Services assessment that Cologuard be performed every three years for patients 50 and older who do not have symptoms of colorectal cancer and who do not have an increased risk of colorectal cancer. Medicare covers Cologuard for individuals age 50-85 fitting these criteria once every three years at no cost to patients.